Based on these biochemical pathways, the CGRP antagonist (human calcitonin gene-related peptide antagonist (CGRP8-37)) may contribute to NTG-induced tolerance, cardiohemodynamic events, and mortality during myocardial infarction. Here, OPA1 is linked to myocardial infarction.